Literature DB >> 28535940

[Postpartum hemorrhage and pregnancy induced hypertension during emergency lower segment cesarean section: dexmedetomidine to our rescue].

Uma Hariharan1.   

Abstract

Dexmedetomidine is a highly selective α-2 agonist which has recently revolutionized our anesthesia and intensive care practice. An obstetric patient presented for emergency cesarean delivery under general anesthesia, with pre-eclampsia and postpartum hemorrhage. In carefully selected cases with refractory hypertension and postpartum hemorrhage, dexmedetomidine can be used for improving overall patient outcome. It was beneficial in controlling both the blood pressure and uterine bleeding during cesarean section in our patient.
Copyright © 2015 Sociedade Brasileira de Anestesiologia. Publicado por Elsevier Editora Ltda. All rights reserved.

Entities:  

Keywords:  Anestesia obstétrica; Cesariana de emergência; Dexmedetomidina; Dexmedetomidine; Emergency cesarean section; Hemorragia pós‐parto; Hipertensão induzida pela gravidez; Obstetric anesthesia; Post‐partum hemorrhage; Pregnancy‐induced hypertension

Mesh:

Substances:

Year:  2017        PMID: 28535940     DOI: 10.1016/j.bjan.2015.09.001

Source DB:  PubMed          Journal:  Rev Bras Anestesiol        ISSN: 0034-7094            Impact factor:   0.964


  3 in total

1.  Dexmedetomidine as a rescue agent during intracranial neurosurgery in the setting of opioid tolerance.

Authors:  S Mackie; D Chambers; J Sebastian
Journal:  Anaesth Rep       Date:  2022-07-19

Review 2.  Can Endothelial Glycocalyx Be a Major Morphological Substrate in Pre-Eclampsia?

Authors:  Marina M Ziganshina; Ekaterina L Yarotskaya; Nicolai V Bovin; Stanislav V Pavlovich; Gennady T Sukhikh
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

3.  Protective effect of dexmedetomidine on kidney injury of parturients with preeclampsia undergoing cesarean section: a randomized controlled study.

Authors:  Qing-Lin Zhang; Lei Wang; Ming-Jun Xu; Tian-Long Wang
Journal:  Biosci Rep       Date:  2019-05-03       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.